Evommune CEO granted 291,420 stock options

Evommune, Inc. President & CEO Luis C. Pena received a grant of employee stock options covering 291,420 shares of common stock.

Rhea-AI Filing Summary

Evommune, Inc. President & CEO Luis C. Pena received a grant of employee stock options covering 291,420 shares of common stock. The options have an exercise price of $26.7700 per share and expire on April 15, 2036. Following this grant, he holds 291,420 derivative securities related to this award.

According to the vesting schedule, one quarter of the options vests on the first anniversary of the grant date, with the remaining options vesting in 36 equal monthly installments, subject to his continuous service. This is a compensation-related award rather than an open-market purchase or sale.

Insider Trade Summary

Grant/Award: 291,420 shares

Grant/Award 1 txn

Insider Pena Luis C.

Role President & CEO

Type	Security	Shares	Price	Value
Grant/Award	Employee Stock Option (Right to Buy)	291,420	$0.00	$0.00

Holdings After Transaction: Employee Stock Option (Right to Buy) — 291,420 contracts (Direct)

Footnotes (1)

1. F1. One fourth (1/4) of the shares subject to the option award shall vest on the first anniversary of the grant date and the remaining shares subject to the option shall vest in thirty-six (36) equal monthly installments thereafter, subject to the Reporting Person's continuous service through such vesting date.

Key Figures

Options granted: 291,420 options Exercise price: $26.7700 per share Expiration date: April 15, 2036 +2 more

5 metrics

Options granted 291,420 options Employee stock option grant to CEO Luis C. Pena

Exercise price $26.7700 per share Stock option exercise price for the grant

Expiration date April 15, 2036 Option award expiration

Underlying shares 291,420 shares Common stock underlying the option grant

Post-transaction derivative holdings 291,420 derivative securities Total options held after this grant

Key Terms

Employee Stock Option (Right to Buy), transaction code "A", vesting, derivative securities, +1 more

5 terms

Employee Stock Option (Right to Buy) financial

"security_title: "Employee Stock Option (Right to Buy)""

transaction code "A" financial

"transaction_code_description: "Grant, award, or other acquisition""

vesting financial

"shares subject to the option award shall vest on the first anniversary"

Vesting is the process by which you earn full ownership of something, like company stock or a retirement benefit, over time. It’s like earning the right to keep a gift piece by piece the longer you stay with a company, making sure employees stay committed before they receive all the benefits.

derivative securities financial

"derivativeTransactionCount": 1"

Financial contracts whose value is tied to the price or performance of another asset, such as a stock, bond, commodity, index, or currency; examples include options, futures and swaps. They matter to investors because they let you protect against price swings, bet on future moves or gain larger exposure with less upfront cash—like using a lever or insurance policy on an investment—so they can amplify gains and losses and help manage portfolio risk.

exercise price financial

"conversion_or_exercise_price": "26.7700""

The exercise price is the fixed amount at which you can buy or sell an asset, like a stock, when using an options contract. It matters because it helps determine whether exercising the option will be profitable or not, depending on the current market price. Think of it as the set price you agree on today to buy or sell later.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What did Evommune (EVMN) CEO Luis C. Pena report in this Form 4?

Luis C. Pena reported receiving a grant of stock options for 291,420 shares of Evommune common stock. These options are part of his compensation and give him the right to buy shares at a fixed exercise price if the options vest and are exercised.

How many Evommune (EVMN) shares are covered by the new stock option grant?

The new stock option grant covers 291,420 underlying shares of Evommune common stock. This entire amount is reflected as derivative securities following the transaction, representing a single award rather than multiple separate grants or open-market transactions.

What is the exercise price and expiration date of the Evommune (EVMN) CEO’s options?

The options have an exercise price of $26.7700 per share and expire on April 15, 2036. This means Pena can choose to buy Evommune shares at $26.7700 any time after vesting and before the 2036 expiration, subject to plan terms.

How do the Evommune (EVMN) CEO’s stock options vest over time?

One fourth of the stock options vests on the first anniversary of the grant date. The remaining options then vest in 36 equal monthly installments, so the award vests gradually over several years, conditioned on his continued service with Evommune.

Does this Evommune (EVMN) Form 4 show the CEO buying or selling shares on the market?

No, the Form 4 shows a grant of employee stock options, not a market trade. The transaction code is “A” for an award or other acquisition, indicating compensation rather than an open-market purchase or sale of Evommune shares.

What is the total derivative position reported for Evommune (EVMN) CEO Luis C. Pena after this grant?

After the transaction, Pena reports holding 291,420 derivative securities related to this option award. This figure reflects the full number of options granted in this filing and represents his reported position from this specific grant.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 04/17/2026 - 05:23 PM EDT Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Pena Luis C.

(Last) (First) (Middle)

C/O EVOMMUNE, INC.

1891 PAGE MILL ROAD

(Street)

PALO ALTO CALIFORNIA 94304

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Evommune, Inc. [ EVMN ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	President & CEO

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
04/16/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Employee Stock Option (Right to Buy)	$26.77	04/16/2026		A		291,420		(1)	04/15/2036	Common Stock	291,420	$0.00	291,420	D

Explanation of Responses:

1. One fourth (1/4) of the shares subject to the option award shall vest on the first anniversary of the grant date and the remaining shares subject to the option shall vest in thirty-six (36) equal monthly installments thereafter, subject to the Reporting Person's continuous service through such vesting date.

Remarks:

	/s/ Gregory S. Moss, Attorney-in-Fact	04/17/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)